Evidence map›Paper›PMID 27118284›Full record

Observational studyBMJ open2016

Prospective observational study protocol to investigate long-term adverse effects of methylphenidate in children and adolescents with ADHD: the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study.

S K Inglis, S Carucci, P Garas, A Häge, T Banaschewski, J K Buitelaar, R W Dittmann, B Falissard, C Hollis, H Kovshoff and 10 more

2 registry-linked trialsOpen access · goldAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMJ open, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01470261 completednot on this map

Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects

TypeobservationalSponsorNHS TaysideRan2012 to 2016Enrolled1,398ConditionsAttention Deficit Hyperactivity Disorder (ADHD)
NCT04964427 nacompletednot on this mapstarted 2021, after this paper: background citation

The Effects of Methylphenidate (MPH) and Non-invasive Brain Stimulation (tDCS) on Inhibitory Control Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

TypeinterventionalSponsorBambino Gesù Hospital and Research InstituteRan2021 to 2022Enrolled26ConditionsAttention Deficit Hyperactivity DisorderArmsMethylphenidate, anodal tDCS, sham tDCS
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Review
  7. The Benefits and Limitations of Stimulants in Treating ADHD.Current topics in behavioral neurosciences · 2022
    Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Observational
  13. Review
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 13 institutions in 8 countries.

S K InglisDivision of Neuroscience, School of Medicine, University of Dundee & Tayside Clinical Trials Unit, University of Dundee, Dundee, UK.
S CarucciChild and Adolescent Neuropsychiatry Unit, Department of Biomedical Science, University of Cagliari, Cagliari, Italy.
P GarasVadaskert Child and Adolescent Psychiatric Hospital, Budapest, Hungary.
A HägeDepartment of Child & Adolescent Psychiatry and Psychotherapy, Medical Faculty Mannheim, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany.
T BanaschewskiDepartment of Child & Adolescent Psychiatry and Psychotherapy, Medical Faculty Mannheim, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany.
J K BuitelaarCognition and Behavior, Department of Cognitive Neuroscience, Radboud University Medical Centre, Donders Institute for Brain, Karakter Child and Adolescent Psychiatry University Centre, Nijmegen, The Netherlands.
R W DittmannDepartment of Child & Adolescent Psychiatry and Psychotherapy, Medical Faculty Mannheim, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany.
B FalissardUnivercity Paris-Sud, Univ. Paris-Descartes, AP-HP, INSERM U1178, Paris, France.
C HollisFaculty of Medicine & Health Sciences, Institute of Mental Health, University of Nottingham, Nottingham, UK.
H KovshoffAcademic Unit of Psychology, University of Southampton, Southampton, UK.
E LiddleFaculty of Medicine & Health Sciences, Institute of Mental Health, University of Nottingham, Nottingham, UK.
S McCarthySchool of Pharmacy, University College Cork, Cork, Ireland.
P NagyVadaskert Child and Adolescent Psychiatric Hospital, Budapest, Hungary.
A NeubertDepartment of Paediatrics and Adolescents Medicine, University Hospital Erlangen, Erlangen, Germany.
E RosenthalEvelina Children's Hospital, St Thomas' Hospital, London, UK.
E Sonuga-BarkeUK and Department of Experimental Clinical & Health Psychology, University of Southampton, Ghent University, Belgium.
I WongUCL School of Pharmacy, 29-39 Brunswick Square, London, UK.
A ZuddasChild and Adolescent Neuropsychiatry Unit, Department of Biomedical Science, University of Cagliari, Cagliari, Italy.
D C CoghillDivision of Neuroscience, School of Medicine, University of Dundee, Dundee, UK.
ADDUCE Consortium
Central Institute of Mental Health · DEUniversity of Cagliari · ITUniversity of Dundee · GBUniversity of Nottingham · GBUniversity of Southampton · GBVadaskert Alapítvány a Gyermekek Lelki Egészségéért · HUEvelina London Children's Healthcare · GBRadboud University Medical Center · NLUniversitätsklinikum Erlangen · DEUniversité Paris Cité · FRUniversity College Cork · IEUniversity College London · GBUniversity Hospital Heidelberg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMethylphenidate is the most frequently used medication for the treatment of attention-deficit/hyperactivity disorder (ADHD) in Europe. Following concerns about its safety, the European Commission called for research into the long-term effects of methylphenidate on children and adolescents with ADHD. The Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) research programme was designed to address this call. At the heart of this programme is a 2-year longitudinal naturalistic pharmacovigilance study being conducted in 27 European sites. METHODS AND ANALYSIS: 3 cohorts of children and adolescents (aged 6-17) living in the UK, Germany, Italy and Hungary are being recruited:Group 1 (Medicated ADHD): 800 ADHD medication-naive children and adolescents with a clinical diagnosis of ADHD about to start methylphenidate treatment for the first time.Group 2 (Unmedicated ADHD): 400 children and adolescents with a clinical diagnosis of ADHD who have never been treated with ADHD medication and have no intention of beginning medication.Group 3 (Non-ADHD): 400 children and adolescents without ADHD who are siblings of individuals in either group 1 or 2.All participants will be assessed 5 times during their 2-year follow-up period for growth and development, psychiatric, neurological and cardiovascular health. The primary outcome measure will be the height velocity SD score. ETHICS AND DISSEMINATION: Ethical approval for the study has been granted by the East of Scotland Research Ethics Service. Following this approval, patient information leaflets and consent forms were translated as necessary and submissions made by lead sites in each of the other 3 countries to their own ethics committees. Following ethical approval in each country, local ethical permissions at each site were sought and obtained as needed. The study's website (http://www.adhd-adduce.org/page/view/2/Home) provides information for researchers, participants and the general public. TRIAL REGISTRATION NUMBER: NCT01470261.

Indexed as

AdolescentAttention Deficit Disorder with HyperactivityCentral Nervous System StimulantsChildFemaleGermanyHumansHungaryItalyLogistic ModelsLongitudinal StudiesMaleMethylphenidatePharmacovigilanceProspective StudiesTreatment OutcomeCentral Nervous System StimulantsMethylphenidateAttention Deficit Hyperactivity DisorderMethylphenidate

Identifiers

PMID27118284
PMCPMC4853973
OpenAlexW2344185757

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.